On January 1, 2025, there was a change in leadership at CSL Innovation GmbH: Dr. Lars Grönke handed over the management to Dr. Martin Vey after approximately four years. Martin Vey brings over 25 years of experience in the biopharmaceutical industry. After studying and earning his doctorate in human biology with a focus on molecular virology at Philipps University Marburg and a research stay at the University of California San Francisco in the USA, he gained extensive experience in research and development (R&D), production, and strategic marketing at CSL. "I look forward to continuing the great work of my predecessor and further developing our site together with our leadership team to continue saving lives with our innovations and improving the quality of life for people with rare diseases," said Vey. He is currently serving as Executive Director in the Plasma Product Development division at CSL Innovation GmbH. He will take on the new role in addition to his current position.
Lars Grönke has significantly shaped the development and advancement of CSL Innovation with great dedication. Under his leadership, the R&D Campus M600 was established, which is now considered a flagship project. He has also been exceptionally committed to building and maintaining local and (inter-)regional partnerships and passionately promoted the expansion of a thriving regional innovation ecosystem. Grönke will now further expand his role as R&D Lead for the important therapeutic area of immunoglobulins.
" I look forward to continuing the great work of my predecessor and further developing our site together with our leadership team. "
Dr. Martin Vey, new Managing Director of CSL Innovation GmbH since 1 January 1 2025
A change that stands for continuity and innovative strength
Lars Grönke will continue to expand his global role as R&D Lead for the therapeutic area of immunoglobulins at CSL. During his tenure as Managing Director, he significantly shaped the development and advancement of CSL Innovation. The R&D Campus M600, one of the largest research and development centers in CSL's global R&D network with over 500 employees, was established during his time as Managing Director. He has also been committed to building and maintaining local and (inter-)regional partnerships in the service of the biotech location Marburg and promoting young talent.
"The dedication and commitment of my predecessor, Lars Grönke, as an important partner for the city and region, universities and academic institutions, as well as the local and regional economy, significantly contribute to the formation of a thriving regional innovation ecosystem," emphasized Vey. "We will continue this commitment." CSL Innovation thus continues to expand its position as a driving force and central component of the Biotech Valley Mittelhessen.
